EAC 2022 Update in Allergy, Asthma and Immunology

June 2, 2022 to June 5, 2022

The EAC 2022 Update in Allergy, Asthma & Immunology meeting will provide learners with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology. Learners will not only gain insights with regard to selecting the best therapeutic alternative for each patient, but they will also have the opportunity to develop novel strategies designed to enhance therapeutic adherence through shared decision making. The format will incorporate problem based learning, uniquely designed to interface with lectures in context to the core issues relevant to the cases.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Eastern Allergy Conference (EAC). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 14 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 14 contact hours.

Commercial Support
This activity is supported in part by independent medical education grants from Stallergenes Greer, CSL Behring and BioCryst.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

At the conclusion of this activity, participants should be able to:
• Describe signaling pathways and their clinical implications in atopic dermatitis
• Outline an endotype, phenotype and guideline-based approach to the treatment of asthma
• Discuss strategies to overcome COVID-19 vaccine misinformation and hesitancy
• Diagnose and manage eosinophilic gastrointestinal disorders
• Diagnose and manage non IgE-mediated drug allergy
• Diagnose and manage hereditary angioedema
• Diagnose and manage chronic urticaria
• Discuss current and future allergy immunotherapy treatment options for respiratory
• Outline an approach to the use of biologics for allergic diseases, including asthma, chronic
urticaria and atopic dermatitis
• Evaluate for potential immunodeficiency
• Discuss the “long COVID-19 syndrome”

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 Attendance
  • 14.00 CBRN
Course opens: 
Course expires: 
Event starts: 
06/02/2022 - 3:00pm CDT
Event ends: 
06/05/2022 - 10:00am CDT

Eastern Allergy Conference Meeting Program

Thursday June 2, 2022
4:15 – 4:55 The Long Covid Syndrome: A conundrum for the Allergist/Immunologist, Joseph Bellanti, MD

4:55 – 5:35 What’s new in AIT, Hal Nelson, MD

5:35 – 6:15 What’s new in EGIDs, Princess Ogbogu, MD

6:15 – 6:30 Panel Discussion: Q & A

Friday, June 3, 2022
7:45 – 8:15 HAE: Managing the difficult to treat patient, Paula Busse, MD

8:15 – 8:45 Bacterial lysate therapy for patients with allergic diseases, Hal Nelson, MD

8:45 – 8:55 Panel Discussion: Q & A

8:55 – 10:15 PBL: A 18-year-old woman with a chronic pruritic rash, Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD, Dana Wallace, MD, Michael Blaiss, MD

10:15 – 11:00 Coffee Break: Visit Exhibits and Posters (nonCME)

11:00 – 11:15 PBL wrap up, Dana Wallace, MD

11:15 – 11:40 Treatment options for moderate to severe atopic dermatitis, Dana Wallace, MD

11:40 – 12:05 Current and future management of CSU/CIndU, Shyam Joshi, MD

12:05 – 12:15 Panel Discussion: Q & A

1:15 – 1:45 New PIDDs and the evolving landscape of clinical immunology, Jordan Orange, MD

1:45 – 2:15 Autoinflammatory disease, Hal Hoffman, MD

2:15 – 2:30 Panel Discussion: Q & A

Saturday, June 4, 2022
7:45 – 8:15 PIDD: Where does genetic testing fit into the diagnostic evaluation, Jordan Orange, MD

8:15 – 8:45 CRSwNP management in the age of biologics, Shyam Joshi, MD

8:45 – 8:55 Panel Discussion: Q & A

8:55 – 10:15 PBL: A 46-year-old woman with dyspnea, wheeze, and cough, Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD, Dana Wallace, MD, Michael Blaiss, MD

10:15 – 11:00 Coffee Break: Visit Exhibits and Posters (nonCME)

11:00 – 11:15 PBL wrap up, Russell Settipane, MD

11:15 – 12:05 Debate: Targeted therapies for specific asthma phenotypes or not?
    Pro – Mark Corbet, MD 
    Con – Michael Blaiss, MD

12:05 – 12:15 Panel Discussion: Q & A

1:15 – 1:45 Optimal management of the older adult with severe asthma, Paula Busse, MD

1:45 – 2:15 Severe pediatric asthma, biologics, and biomarkers, Andrew Liu, MD

2:15 – 2:30 Panel Discussion: Q & A

Sunday, June 5, 2022
8:15 – 8:45 Eosinophilia: Differential diagnosis, evaluation, and management, Princess Ogbogu, MD

8:45 – 9:15 Update on cold induced syndromes for the allergist, Hal Hoffman, MD

9:15 – 9:45 Non-IgE-mediated drug allergies, Shyam Joshi, MD

9:45 – 10:00 Panel Discussion: Q & A

All relevant financial relationships have been mitigated.

The individuals listed below disclose the following financial relationships:

Michael Blaiss, MD – Speaker
Advisory Board – ALK, AstraZeneca, Merck, Regeneron
Research Grant – Merck
Consultant- ALK, Sanofi Genzyme, Covis, Perrigo, TerSera Pharma, Lanier Biopharmaceuticals
Speaker- Merck, Regeneron, Sanofi Genzyme

Don Bukstein, MD – Speaker
Speaker – AstraZeneca, Teva, Regeneron

Paula Busse, MD – Speaker
Speaker – BioCryst
Advisor – CSL Behring, CVS, Takeda, Regeneron, Novartis

Mark Corbett, MD – Speaker
Speaker – Sanofi Regeneron, OptiNose
Advisor – AstraZeneca, ALK, Takeda

William Corrao, MD – Planner
Speaker – Boehringer Ingelheim, GSK

Ray Davis, MD – Speaker
Advisor – Shire, Bayalta, Circassia, Takeda, Genentech, Novartis, ALK, DBV Technologies, Regeneron, Sanofi, TEVA

Hal Hoffman, MD – Speaker
Speaker –Novartis
Independent Contractor– Novartis, Kiniksa, Aclaris, Takeda, Zomagen

Shyam Joshi, MD – Speaker
Advisor – Sanofi, BioCryst, Takeda, Leo Pharma

Andrew Liu, MD – Speaker
Research Grant – Avillion, ResMed/Propeller Health, Phadia/ThermoFisher
Advisor – Avillion, ResMed/Propeller Health, Phadia/ThermoFisher, Labcorp

Harold Nelson, MD – Speaker
Speaker – ALK

Princess Ogbogu, MD – Speaker
Research Grant – AstraZeneca, GSK
Advisor – AstraZeneca, GSK

Jordan Orange, MD – Speaker
Speaker – SOBI
Advisor – CSL Behring, Grifols, Editas, EdiTy, TEVA, Takeda, Johnson & Johnson

Robert Settipane, MD – Planner
Independent Contractor - AstraZeneca, BioCryst, GSK, Regeneron, Teva

Russell Settipane, MD – Planner/Speaker
Speaker – AbbVie, Amgen, AstraZeneca, BioCryst, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Grifols, Pharming, Pfizer, Regeneron, Sanofi, Takeda 
Advisory Board – AbbVie, Aimmune, AstraZeneca, BioCryst, Boehringer Ingelheim, DBV Technologies, GlaxoSmithKline, Kalvista, Pharming, Pfizer
Independent Contractor – AstraZeneca, GlaxoSmithKline, TEVA, BioCryst, Regeneron  

Dana Wallace, MD – Speaker
Speaker – Sanofi
Advisory Board – Bryn, Sanofi

The following have no relevant financial relationships to disclose:

Joseph Bellanti, MD – Planner/Speaker
William Greisner, III, MD – Planner/Moderator/Reviewer 
Ginny Loiselle – Coordinator
Katelyn Loiselle, BSN, RN – Planner 
Michael Slaughter, MD – Planner/Moderator/Reviewer
Kelli Wilson – Planner


Available Credit

  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 Attendance
  • 14.00 CBRN
Please login or create an account to take this course.